8-K: Capricor Therapeutics Announces Positive Clinical Trial Progress and Second Quarter 2024 Financial Results

Capricor Therapeutics reported positive clinical trial updates for its lead drug candidate, deramiocel, and announced its second quarter 2024 financial results, including a net loss of $11.0 million.

Summary

• Capricor Therapeutics announced its second quarter 2024 financial results and provided a corporate update.
• The company reported a net loss of approximately $11.0 million, or $0.35 per share, for the second quarter of 2024, compared to a net loss of approximately $7.4 million, or $0.29 per share, for the second quarter of 2023.
• Revenues for the second quarter of 2024 were approximately $4.0 million, compared to approximately $3.9 million for the same period in 2023.
• Total operating expenses for the second quarter of 2024 were approximately $15.6 million, compared to approximately $11.7 million for the second quarter of 2023.
• The company's cash, cash equivalents, and marketable securities totaled approximately $29.5 million as of June 30, 2024, compared to approximately $39.5 million as of December 31, 2023.
• Capricor raised approximately $2.1 million in net proceeds through issuances of common stock in the second quarter of 2024.
• The company completed enrollment for its HOPE-3 Phase 3 clinical trial of deramiocel in Duchenne muscular dystrophy (DMD), with top-line data from Cohort A expected in the fourth quarter of 2024.
• Positive 3-year data from the HOPE-2 open-label extension study showed a statistically significant benefit of +3.7 points (p<0.001) in the PUL v2.0 total score compared to an external comparator dataset.
• Capricor had a positive pre-BLA meeting with the FDA to discuss the rolling BLA submission schedule for deramiocel.
• The company is also advancing its StealthX exosome platform technology and exploring partnership opportunities.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive clinical trial progress and a positive pre-BLA meeting, but also a significant increase in net loss and a decrease in cash reserves. The company's future is dependent on successful clinical trial results, regulatory approvals, and securing additional funding.

Positives

• The company completed enrollment for the HOPE-3 Phase 3 clinical trial, a significant milestone.
• Positive 3-year data from the HOPE-2 open-label extension study demonstrates the potential long-term benefit of deramiocel.
• The positive pre-BLA meeting with the FDA is a crucial step towards regulatory approval of deramiocel.
• The company's StealthX exosome platform is progressing with a vaccine candidate selected for Project NextGen.
• Capricor secured $2.1 million in net proceeds through stock issuances, bolstering its financial position.
• The company's revenue increased to $4.0 million in the second quarter of 2024 compared to $3.9 million in the same period of 2023.

Negatives

• The company reported a net loss of $11.0 million for the second quarter of 2024, an increase from the $7.4 million loss in the same period of 2023.
• Total operating expenses increased to $15.6 million in the second quarter of 2024, compared to $11.7 million in the second quarter of 2023.
• The company's cash position decreased from $39.5 million at the end of 2023 to $29.5 million as of June 30, 2024.
• The company expects its current cash resources to be sufficient only into the first quarter of 2025.

Risks

• The company's cash resources are projected to last only into the first quarter of 2025, requiring additional funding.
• The company is dependent on the success of its clinical trials and regulatory approvals for deramiocel.
• The company faces competition in the development of therapies for rare diseases.
• The company's StealthX platform is still in preclinical development and may not yield successful products.
• The company's financial performance is subject to fluctuations in revenue and expenses.
• The company's ability to secure partnerships in Europe is uncertain.

Future Outlook

Capricor believes its current cash resources will be sufficient to cover expenses into the first quarter of 2025, excluding potential milestone payments and strategic capital use. The company plans to announce the outcome of the pre-BLA meeting, present additional HOPE-2 data, and report top-line data from HOPE-3 (Cohort A) in the fourth quarter of 2024.

Management Comments

• We continue to make significant progress across our pipeline as we move closer to the filing of our Biologics License Application (BLA) of our lead asset, deramiocel (also referred to as CAP-1002), for the treatment of Duchenne muscular dystrophy (DMD), said Linda Marbn, Ph.D., Capricors chief executive officer.
• We recently conducted a positive pre-BLA meeting with the U.S. Food and Drug Administration (FDA) and we will provide further updates on our plans as they become available.
• Furthermore, our recently announced 3-year HOPE-2 open label extension (OLE) data gives us confidence in the totality of safety and efficacy data we have seen year over year and the potential benefit that deramiocel can provide to patients with DMD.
• Lastly, on the corporate front, we remain focused on securing a partnership in Europe in order to support our balance sheet as we move towards major inflection points over the next several quarters.
• In addition, we continue to progress our proprietary StealthX platform technology as part of our long-term strategy to leverage exosomes for therapeutic development.
• We continue to explore partnership opportunities and other non-dilutive sources of funding to advance this program.

Industry Context

Capricor's focus on cell and exosome-based therapeutics aligns with the growing interest in these modalities for treating rare diseases. The company's progress in DMD, a disease with limited treatment options, positions it to potentially address a significant unmet medical need. The collaboration with NIAID for a SARS-CoV-2 vaccine also reflects the broader industry efforts to develop innovative vaccines.

Comparison to Industry Standards

• Capricor's 3-year HOPE-2 OLE data showing a +3.7 point improvement in PUL v2.0 score is a positive result compared to natural history data for DMD patients, suggesting a clinically meaningful benefit.
• Other companies developing DMD therapies, such as Sarepta Therapeutics with its gene therapy and exon-skipping drugs, have also shown positive results, but direct comparisons are difficult due to different trial designs and endpoints.
• The completion of enrollment for the HOPE-3 trial is a significant milestone, comparable to other companies advancing late-stage clinical trials for rare diseases.
• The positive pre-BLA meeting with the FDA is a key step, similar to other companies seeking regulatory approval for their therapies.
• Capricor's cash position of $29.5 million is relatively low compared to some larger biotech companies, highlighting the need for additional funding or partnerships.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the progress of its clinical trials.
• Employees are impacted by the company's financial stability and the success of its research and development efforts.
• Patients with DMD and other rare diseases may benefit from the company's development of new therapies.
• Partners and collaborators are impacted by the company's progress and financial stability.
• Creditors are impacted by the company's financial performance and ability to repay debts.

Next Steps

• Announce the outcome from the pre-BLA meeting in the third quarter of 2024.
• Present additional 3-year data from the HOPE-2 OLE study at a medical meeting in the fourth quarter of 2024.
• Report top-line data from HOPE-3 (Cohort A) in the fourth quarter of 2024.
• Continue to explore opportunities for additional partnerships outside of the U.S. and Japan.
• Provide updates on the NIAID collaboration for the StealthX vaccine as they become available.
• Continue to explore opportunities for partnerships and non-dilutive sources of funding to support advancement of the StealthX exosome platform technology.

Key Dates

Keywords

deramiocel, Duchenne muscular dystrophy, DMD, cell therapy, exosome, StealthX, clinical trial, FDA, Biologics License Application, BLA, rare disease, vaccine, financial results